论文部分内容阅读
2006年12月18日——12月11日《临床肿瘤学》“新动向”版发文报道:美国临床肿瘤协会(ASCO)和美国病理学家学院(CAP)联合发表指南,推荐所有浸润性乳腺癌的病人都接受人表皮生长因子受体2(HER2)的水平的检测。
December 18, 2006 - December 11 The issue of Clinical Oncology and New Trends reports: The American Society of Clinical Oncology (ASCO) and the American College of Pathologists (CAP) jointly published guidelines recommending that all infiltration Patients with breast cancer are tested for the level of human epidermal growth factor receptor 2 (HER2).